GlaxoSmithKline News and Research

RSS

Breakthrough research could transform the landscape of ovarian cancer treatment

In a major scientific breakthrough, newly published research from an international consortium led by the University of Minnesota's Masonic Cancer Center has the potential to transform the landscape of ovarian cancer treatment.

27 Feb 2024

Optimizing chemotherapy for older adults with advanced cancer

Standard chemotherapy regimens, which are mostly based on testing in relatively young and healthy patients, may do more harm to older adults with cancer who often struggle with other health issues.

16 Feb 2024

SGLT2 inhibitors linked to lower risk of kidney stones in patients with type 2 diabetes

Rates of kidney stones are on the rise in the United States and around the world. Type 2 diabetes is associated with increased risk of kidney stones, but some forms of treatment for this condition may also have the benefit of lowering risk of kidney stones.

31 Jan 2024

The FTC is attacking drugmakers’ ‘patent thickets’

The Federal Trade Commission has challenged the validity of over 100 drug product patents, focusing on devices used to deliver medicines, like inhalers and autoinjectors, in an effort to increase competition and potentially lower some prices.

31 Jan 2024

Study analyzes the use of tissue-agnostic therapeutics in patients with primary brain tumors

Researchers from Miami Cancer Institute, part of Baptist Health South Florida, today published a study in Trends in Cancer that analyzes the use of tissue-agnostic therapeutics in patients with primary brain tumors (PBTs).

19 Jan 2024

People with NCDs disproportionately impacted by the COVID-19 pandemic, report shows

Researchers at the Montreal Behavioural Medicine Centre (MBMC) say people with noncommunicable diseases (NCDs) such as heart disease, cancer, diabetes, or chronic lung ailments were disproportionately impacted by the COVID-19 pandemic.

9 Jan 2024

New study challenges "gold standard" opioid treatment for cancer pain

Researchers examining the data on opioids for pain caused by cancer have found surprisingly large gaps in evidence regarding the true benefits of these medicines for cancer pain.

18 Dec 2023

New study casts doubt on effectiveness of opioids for cancer pain

The world's largest review on opioid medicines for cancer pain has found it is unclear whether some commonly used opioid medicines are better than a placebo and suggests that non-opioid medicines, including aspirin, may be as effective as opioids.

18 Dec 2023

New drug combo shows promise in targeting RAS-mutant multiple myeloma

The combination of a drug and a protein fragment prevents the growth of blood cancer cells, a new study in mice shows.

11 Dec 2023

Dr Farid Khan, PharmaKure CEO, to speak on Alzheimer's diagnosis and treatment at Biotech Outsourcing Strategies Manchester 2023

Talk to focus on the spinout journey from drug repurposing to clinical trials for diagnosing and treating Alzheimer’s Disease.

28 Nov 2023

COVID-19 vaccination before first infection may reduce risk of developing long COVID

Receiving at least one dose of a covid-19 vaccine before the first infection is strongly associated with a reduced risk of developing post-covid-19 condition, commonly known as long covid, finds a study published by The BMJ today.

22 Nov 2023

One in five individuals taking nirmatrelvir-ritonavir therapy found to experience rebound COVID

A new study by investigators from Mass General Brigham found that one in five individuals taking Nirmatrelvir-ritonavir therapy, commonly known as Paxlovid, to treat severe symptoms of COVID-19, experienced a positive test result and shedding of live and potentially contagious virus following an initial recovery and negative test - a phenomenon known as virologic rebound.

13 Nov 2023

NanoSyrinx appoints Anthony Johnson as Non-Executive Director

Appointment of Big Pharma executive strengthens leadership team to drive ambitious growth strategy.

From NanoSyrinx 13 Nov 2023

Live shingles vaccine highly effective in the first year after vaccination and then wanes substantially

The effectiveness of live zoster (shingles) vaccine is highest in the first year after vaccination and then wanes substantially.

8 Nov 2023

Study sheds new light on the variety of cellular causes of rheumatoid arthritis

Rheumatoid arthritis (RA) is an autoimmune disease characterized by inflammation that leads to pain, joint damage, and disability, which affects approximately 18 million people worldwide.

8 Nov 2023

Japanese study uncovers protective role of nasal microbiome in eosinophilic chronic rhinosinusitis

Like other countries in the world, Japan has witnessed a worrisome increase in the prevalence of chronic rhinosinusitis (CRS) over the last decade.

6 Nov 2023

Live vaccinations found to be safe for pediatric organ transplant recipients

Live vaccinations provided to children who previously received liver or kidney transplants were found to be safe and prompted an immune response to guard against several life-threatening conditions, according to a new study published Oct. 12, 2023, in JAMA Network Open.

16 Oct 2023

RSV in seniors: Less common than COVID-19, but hits harder, CDC study reveals

In a recent CDC's MMWR study, researchers found that while respiratory syncytial virus (RSV) infections are less common than COVID-19 and influenza in Americans aged 60+ years, they result in much more severe clinical outcomes. This insight supports the CDC's recommendation for RSV vaccination in older adults, emphasizing its potential in preventing severe respiratory disease.

10 Oct 2023

Cough analysis as a tool to predict severe pneumonia in COVID-19 patients

While most individuals impacted by COVID-19 experience milder symptoms and recover within a few weeks, the global pandemic caused by the SARS-CoV-2 virus continues to pose a significant health challenge.

21 Sep 2023

Is the new bivalent COVID-19 vaccine the booster we've been waiting for?

The bivalent COVID-19 vaccine developed by GSK and Sanofi shows promising results with a 64.7% overall effectiveness against symptomatic COVID-19, according to a phase 3 trial. The vaccine performs especially well as a booster, achieving 75.9% efficacy in non-naïve subjects.

17 Sep 2023